

SEQUENCE LISTING

<110> Schenk, Dale B.
Neuralab Limited

<120> Prevention and Treatment of Amyloidogenic Disease

<130> 15270J-004720US

<140> 09/201,430

<141> 1998-11-30

<150> US 60/067,740

<151> 1997-12-02

<150> US 60/080,970

<151> 1998-04-07

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<223> human Abeta42 beta-amyloid peptide

<400> 1

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30

Gly Leu Met Val Gly Val Val Ile Ala
35 40

<210> 2

<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Abeta1-12
peptide with carboxyl terminal Cys residue
inserted

<400> 2
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys
1 5 10

<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Abeta1-5
peptide with carboxyl terminal Cys residue
inserted

<400> 3
Asp Ala Glu Phe Arg Cys
1 5

<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Abeta33-42
peptide with carboxyl terminal Cys residue
inserted

<220>
<221> MOD_RES
<222> (2)
<223> Xaa = amino heptanoic acid

<400> 4

Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
1 5 10

<210> 5

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Abeta13-28
peptide with carboxyl terminal Cys residue
inserted and two added Gly residues

<220>

<221> MOD_RES

<222> (1)

<223> Xaa = acetyl histidine

<400> 5

Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
1 5 10 15

Gly Gly Cys